Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03274219 · ClinicalTrials.gov registry record · Phase 1
Study of bb21217 in Multiple Myeloma
A Phase 1 study of Multiple Myeloma, sponsored by 2seventy bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 11
- Study locations
NCT03274219: Completed Phase 1 study of Multiple Myeloma, sponsored by 2seventy bio.
NCT03274219 is a Phase 1 study of Multiple Myeloma that has completed, run by 2seventy bio. The registered enrollment target is 72 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (87% lower). The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03274219, a Phase 1 study of Multiple Myeloma, has completed, sponsored by 2seventy bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 11
- Study locations
Study Summary
Study CRB-402 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb21217 in adults with relapsed/refractory multiple myeloma (MM).
Primary Outcome
Incidence of adverse events (AEs) and abnormal laboratory test results, including dose limiting toxicities (DLTs)
Conditions Studied
Interventions
- BIOLOGICAL bb21217
Study Locations (11)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
California
- UCSF Medical Center at Parnassus - San Francisco
Florida
- H. Lee Moffitt Cancer Center - Tampa
Georgia
- Winship Cancer Insitute, Emory University - Atlanta
Illinois
- University of Chicago - Chicago
Minnesota
- Mayo Clinic Cancer Center - Rochester
New Jersey
- John Theurer Cancer Center at Hackensack UMC - Hackensack
New York
- Mount Sinai Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2017-08-16 |
| Est. Completion | 2022-12-02 |
| Phase | Phase 1 |
What the finished NCT03274219 record still lists
NCT03274219 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which bb21217 is the first listed.
NCT03274219 lists 11 locations in 9 states (Massachusetts, California, Florida).
Frequently Asked Questions
What is clinical trial NCT03274219 about?
NCT03274219 is a clinical study titled "Study of bb21217 in Multiple Myeloma". Study CRB-402 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb21217 in adults with relapsed/refractory multiple myeloma (MM).
What is the current status of trial NCT03274219?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2017-08-16. Estimated completion is 2022-12-02.
What conditions does trial NCT03274219 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT03274219?
The interventions under investigation include: bb21217 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03274219?
This trial is sponsored by 2seventy bio, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03274219 being conducted?
This trial has 11 study locations across California, Florida, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03274219's enrollment target sits among peer trials
72 210th of 438 higher than 228 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI